Recent Stories

Ideal Protein on AHA's Treating Obesity as a Disease Article

Partner News  |  Published: Tuesday, October 25, 2016

Ideal Protein's COO, Tim Callahan, comments on the American Heart Association's latest article on obesity: "Obesity is a chronic disease and should be treated as such. To arrest obesity and mitigate associated health conditions,  people need tools to effect a sustainable lifestyle change," said Tim Callahan, Chief Operating Officer of Ideal Protein. "Many healthcare professionals realize that the simplistic advice of 'eat less, exercise more' isn't working long-term, and are approaching obesity with integrated, medically-developed protocols that include nutritional guidance, ongoing practitioner oversight, education and counseling."


MedAxiom Partners with Objective Medical Systems to Introduce Intuitive Information System for Clinical Decision Making

Partner News  |  Published: Tuesday, October 18, 2016

MedAxiom is pleased to announce a new corporate partnership with Objective Medical Systems (OMS), a technology innovator within the cardiovascular health care industry.


Health Lumen Offers Analytic Solutions to Improve Patient Care and Reduce Costs

Partner News  |  Published: Friday, September 16, 2016

MedAxiom is pleased to introduce its newest corporate partner, Health Lumen—a progressive company of health care experts focused on data analytics that offer cardiovascular programs innovative, affordable and scalable analytics solutions amidst the ever-changing health care landscape. The partnership aims to help MedAxiom member organizations achieve better patient outcomes and reduced costs.


MedAxiom partners with ChronicCareIQ to bring first automated chronic care management system to cardiovascular care providers

Partner News  |  Published: Tuesday, September 13, 2016

New patient engagement technology is moving patient care into the future, as providers adapt to new models of care and payment reform under Medicare. That is why MedAxiom is very pleased to announce a new partnership with ChronicCareIQ, creator of the first automated chronic care management solution.


Cambridge Therapeutic Technologies Joins MedAxiom Community as a Corporate Partner

Partner News  |  Published: Wednesday, September 7, 2016

MedAxiom is pleased to announce Cambridge Therapeutic Technologies (CTT) as a corporate partner. CTT has developed an innovative, patient-centric medication adherence solution available to cardiovascular practices across the country.


Importance of Myocardial Perfusion Positron Emission Tomography Recognized in New Joint Position Statement by the American Society of Nuclear Cardiology and the Society of Nuclear Medicine and Molecular Imaging

Partner News  |  Published: Wednesday, August 31, 2016

MONROE TOWNSHIP, N.J., Aug. 29, 2016 /PRNewswire/ -- Bracco Diagnostics Inc. (BDI), the U.S. subsidiary of Bracco Imaging S.p.A., a global leading company in the diagnostic imaging business, announced today that the American Society for Nuclear Cardiology (ASNC) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have e-published a PositionREAD MORE 

Astellas' Tyler Marciniak Named to PRWeek's 40 Under 40

Partner News  |  Published: Thursday, August 4, 2016

NORTHBROOK, Ill., Aug. 4, 2016 /PRNewswire/ -- Tyler Marciniak, corporate affairs director and head of product communications for Astellas Americas, has been named to PRWeek's 2016 "40 Under 40" List. The list honors 40 professionals under age 40 who are redefining the role of communications, public relations and marketing across top organizations in their fields.


Medtronic CoreValve(TM) Evolut(TM) R System First TAVI to Receive CE Mark for Intermediate Risk Aortic Stenosis Patients

Partner News  |  Published: Tuesday, August 2, 2016

DUBLIN - August 1, 2016 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européenne) mark for the self-expanding, recapturable and repositionable CoreValve(TM) Evolut(TM) R System to treat aortic stenosis patients who are at intermediate risk for open-heart surgery as determined by a heart team. The Evolut R System is the first transcatheter aortic valve implantation (TAVI) therapy to obtain an expanded indication in Europe for this patient population.


Items 57-64 of 116